(Q43033653)

12 November 2017

0 references

Consensus interferon: tailored therapy and the impact of adherence (English)

1 reference

12 November 2017

1

1 reference

PubMed ID

21259073

12 November 2017

language of work or name

1 reference

1 March 2011

1 reference

Digestive Diseases and Sciences

12 November 2017

1 reference

12 November 2017

56

1 reference

12 November 2017

3

1 reference

12 November 2017

631-634

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-011-1563-8

12 November 2017

0 references

cites work

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1563-8

U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21259073

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21259073

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21259073

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10620-011-1563-8

1 reference

12 November 2017

1 reference

PubMed ID

21259073